

13 February 2026

**Triple Point Venture VCT plc**

(the "Company")

**Offer for Subscription - over-allotment facility**

The Board of Triple Point Venture VCT Plc confirms that they have resolved to utilise the remaining £10m of the over-allotment facility of £20m in relation to the Company's offer for subscription (the "Offer"). This increases the amount that can be raised under the Offer to £30m.

A copy of the prospectus is available, free of charge, from the registered office of the Company at The Scalpel 18th Floor, 52 Lime Street, London, EC3M 7AF. A copy of the prospectus is also available on the Company's website: <https://www.triplepoint.co.uk/current-vcts/triple-point-venture-vct-plc/s2539/>

The prospectus has been submitted to the National Storage Mechanism and is available for viewing at the following website: <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>

**FOR FURTHER INFORMATION ON THE COMPANY, PLEASE CONTACT**

**Triple Point Investment Management LLP  
(Investment Manager)**

Tel: 020 7201 8989

Seb Wallace  
Jack Rose

The Company's LEI is 213800AOOAQA5XQDEA89

Further information on the Company can be found on its website  
<https://www.triplepoint.co.uk/current-vcts/triple-point-venture-vct-plc/s2539/>

**NOTES:**

The Company is a Venture Capital Trust incorporated in July 2010 and was established to fund small and medium sized enterprises. The Investment Manager is Triple Point Investment Management LLP.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCGPUUWPUPQGQW